Rifaxin 200 Tablet: Each film coated tablet contains Rifaximin BP 200 mg.
Rifaxin550 Tablet: Each film coated tablet contains Rifaximin BP 550 mg.

Rifaximin  is  a  non-aminoglycoside  semi-synthetic,  nonsystemic  antibiotic  derived  from  rifamycin.Rifaximin  acts  by  binding  to  the  beta-subunit  of  bacterial  deoxyribonucleic  acid (DNA)-dependent  ribonucleic  acid  (RNA)  polymerase  enzyme  resulting  in  inhibition  of  bacterial  RNA  synthesis

Rifaxin tablets can be administered orally with or without food

All  medicines  may  cause  side  effects  but  many  people  have  no  or  minor  side  effects. Common side effects of Rifaximin include dizziness, gas, headache, nausea, tiredness.

Rifaximin  tablets  are  contraindicated  in  patients  with  a  hypersensitivity  to Rifaximin, any of the rifamycin antimicrobial agents, or any of the components in Rifaximin tablets

Pregnancy:  Pregnancy  category  'B1 There  are  no  adequate  and  well-controlled  studies  in  pregnant  women.  Because  animal  reproduction  studies  are  not  always  predictive  of  human  response, this drug should be used during pregnancy only if clearly needed.
Lactation: It is not known whether Rifaximinis excreted in human milk. Because many drugs are  excreted  in  human  milk  and  because  of  the  potential  for  adverse  reactions  in  nursing  infants from Rifaximin tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Rifaxin 200 Tablet: Each box contains 2x8's tablets in Alu-Alu blister pack.
Rifaxin 550 Tablet: Each box contains 1x8's tablets in Alu-Alu blister pack

Although in vitro studies demonstrated the potential of Rifaximin to interact
with cytochrome P 450  3A4 (CYP3A4), a clinical drug-drug interaction study demonstrated that Rifaximin  did  not  significantly  affect  the  pharmacokinetics  of  midazolam.  An  additional  clinical  drug-drug interaction study showed no effect of Rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P 450  isoenzymes are not expected

No specific information is available on the treatment of overdosage with Rifaximin.  In clinical  studies  at  doses  higher  than  the  recommended  dose,  adverse  reactions  were  similar  in  subjects  who  received  doses  higher  than  the  recommended  dose  and  placebo.  In  the  case  of  overdosage,  discontinue  Rifaximin,  treat  symptomatically,  and  institute  supportive  measures  as  required

The safety and effectiveness of Rifaximin 200 mg in pediatric patients less than 12
years of age have not been established. The safety and effectiveness of Rifaximin 550 mg have not been established in patients less than 18 years of age.Geriatric Use:Clinical studies of Rifaximin200 mg tablets did not include sufficient numbers ofsubjects  aged  65  and  over  to  determine  whether  they  respond  differently  than  younger  subjects.  In  the  controlled  trial  with  Rifaximin 550  mg,  19.4%  were  65  and  over,  while  2.3%  were  75  and  over.  No  overall  differences  in  safety  or  effectiveness  were  observed  between  these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out

Renal  Insufficiency:
  The  pharmacokinetics  of  Rifaximin  in  patients  with  impaired  renal   function has not been studied

Hepatic  Insufficiency:  No  dosage  adjustment  with  Rifaximin  is  necessary  due  to  its  limited  systemic absorption. Nonetheless, caution should be exercised when Rifaximin is administered to patients with severe hepatic impairment

Store in a cool and dry place, protected from light. Keep out of the reach of children.